1500032L24Rik Inhibitors
Chemical inhibitors of 1500032L24Rik function by targeting various signaling pathways and enzymes that are crucial for cellular processes such as cell cycle progression, survival, and proliferation. Palbociclib, for instance, acts by inhibiting CDK4/6, which are essential for the phosphorylation of the retinoblastoma protein (Rb). This phosphorylation is a key step in the regulation of the cell cycle, and its inhibition can lead to the functional inhibition of 1500032L24Rik by arresting the cell cycle. Similarly, trametinib, cobimetinib, and selumetinib inhibit MEK1/2 within the MAPK/ERK pathway. This inhibition disrupts the signaling that is necessary for cell differentiation and proliferation, processes in which 1500032L24Rik is involved.
Other inhibitors like axitinib, sunitinib, and sorafenib target receptor tyrosine kinases such as VEGFRs and PDGFRs. These receptors are involved in promoting angiogenesis and cell survival, and their inhibition can disrupt cellular processes supported by VEGFR-mediated signaling, leading to the functional inhibition of 1500032L24Rik. Erlotinib and gefitinib specifically inhibit EGFR tyrosine kinase, which is involved in cell proliferation and survival, thus disrupting EGFR-driven cellular processes. Lapatinib extends this inhibition to HER2/neu in addition to EGFR, impairing cell growth and proliferation even further. Dasatinib, with its broad spectrum of targets including BCR-ABL and SRC family kinases, blocks signaling pathways that contribute to cell growth and proliferation. Finally, crizotinib inhibits ALK and ROS1 tyrosine kinases, blocking signaling pathways that support cell survival and proliferation, thus functionally inhibiting 1500032L24Rik. Each of these chemicals acts through its specific mechanism to disrupt the signaling pathways and cellular functions that are essential for the normal function of 1500032L24Rik.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib is a CDK4/6 inhibitor. Inhibition of CDK4/6 prevents phosphorylation of Rb, which is a regulator of cell cycle progression. As 1500032L24Rik is involved in cell cycle regulation, inhibiting CDK4/6 can lead to the functional inhibition of 1500032L24Rik by preventing cell cycle progression. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib is an EGFR tyrosine kinase inhibitor. EGFR signaling is involved in cell proliferation and survival. Inhibition of EGFR can functionally inhibit 1500032L24Rik by disrupting EGFR-driven cellular processes that are necessary for the proper function of 1500032L24Rik. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Lapatinib is a dual tyrosine kinase inhibitor that targets both EGFR and HER2/neu. Inhibiting these receptors can disrupt downstream signaling pathways essential for cell growth and proliferation, which can lead to the functional inhibition of 1500032L24Rik by impairing the cellular processes it is involved in. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib is a receptor tyrosine kinase inhibitor that targets PDGFRs, VEGFRs, and other receptors. By inhibiting these receptors, Sunitinib can functionally inhibit 1500032L24Rik by disrupting the signaling pathways crucial for cell survival and proliferation. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a kinase inhibitor that targets RAF kinase, VEGFR, and PDGFR. Inhibition of these kinases can functionally inhibit 1500032L24Rik by impeding the signaling pathways necessary for cell proliferation and survival, which 1500032L24Rik is associated with. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib is a MEK inhibitor which leads to the inhibition of the MAPK/ERK pathway. By inhibiting this pathway, Trametinib can functionally inhibit 1500032L24Rik by disrupting downstream signaling that would contribute to the cellular roles of 1500032L24Rik. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
Selumetinib is an inhibitor of MEK1/2, which are critical in the MAPK/ERK pathway. Inhibiting MEK1/2 with Selumetinib can functionally inhibit 1500032L24Rik by preventing the activation of downstream components in the pathway that 1500032L24Rik is involved with. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a tyrosine kinase inhibitor with targets that include BCR-ABL and SRC family kinases. By inhibiting these kinases, Dasatinib can functionally inhibit 1500032L24Rik by preventing the signaling that contributes to the protein's role in cell growth and proliferation. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is an inhibitor of EGFR tyrosine kinase, which plays a role in cell proliferation. Inhibition of EGFR by Gefitinib can lead to functional inhibition of 1500032L24Rik by disrupting the EGFR signaling pathways that are essential for the protein's cellular function. | ||||||